Bisphosphonate Use and Reduced All-Cause Mortality in Korean Women Older than 50 Years: A Nationwide Sample Cohort Study.

Q2 Medicine

Journal of Bone Metabolism Pub Date : 2025-11-01 Epub Date: 2025-11-30 DOI:10.11005/jbm.25.933

Soon Young Park, Jisoo Lee, Youjin Lee, Jung-Wee Park, Young-Kyun Lee

{"title":"Bisphosphonate Use and Reduced All-Cause Mortality in Korean Women Older than 50 Years: A Nationwide Sample Cohort Study.","authors":"Soon Young Park, Jisoo Lee, Youjin Lee, Jung-Wee Park, Young-Kyun Lee","doi":"10.11005/jbm.25.933","DOIUrl":null,"url":null,"abstract":"Background: The survival impact of bisphosphonates (BPs) remains uncertain, particularly in East Asian populations, where new-user analyses have been limited.Methods: This was a retrospective, new-user cohort study using the Korean National Health Insurance Service-National Sample Cohort (2002-2011). We identified new users of BPs (N=41,854), and a 1:1 age-matched control group (N=41,854) among women aged ≥ 50 years. Participants were followed for all-cause mortality for up to 10 years. Multivariable Cox proportional hazards models were used to calculate hazard ratios (HRs), adjusting for age and the Charlson Comorbidity Index.Results: A total of 83,708 women were included. Compared with the control group, the risk of all-cause mortality was lower in BP group. BP users showed adjusted HR of 0.47 (95% confidence interval, 0.44-0.49; P<0.001) compared to controls.Conclusions: In this large, nationwide Korean cohort, initiating BPs was associated with a reduced risk of all-cause mortality in women aged 50 and older. These findings suggest that BPs may have survival benefits beyond fracture prevention.","PeriodicalId":15070,"journal":{"name":"Journal of Bone Metabolism","volume":"32 4","pages":"323-330"},"PeriodicalIF":0.0000,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12718989/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Bone Metabolism","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.11005/jbm.25.933","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/11/30 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The survival impact of bisphosphonates (BPs) remains uncertain, particularly in East Asian populations, where new-user analyses have been limited.

Methods: This was a retrospective, new-user cohort study using the Korean National Health Insurance Service-National Sample Cohort (2002-2011). We identified new users of BPs (N=41,854), and a 1:1 age-matched control group (N=41,854) among women aged ≥ 50 years. Participants were followed for all-cause mortality for up to 10 years. Multivariable Cox proportional hazards models were used to calculate hazard ratios (HRs), adjusting for age and the Charlson Comorbidity Index.

Results: A total of 83,708 women were included. Compared with the control group, the risk of all-cause mortality was lower in BP group. BP users showed adjusted HR of 0.47 (95% confidence interval, 0.44-0.49; P<0.001) compared to controls.

Conclusions: In this large, nationwide Korean cohort, initiating BPs was associated with a reduced risk of all-cause mortality in women aged 50 and older. These findings suggest that BPs may have survival benefits beyond fracture prevention.

Abstract Image

查看原文本刊更多论文

韩国50岁以上妇女使用双膦酸盐可降低全因死亡率：一项全国抽样队列研究

背景：双膦酸盐（bp）对生存的影响仍然不确定，特别是在东亚人群中，新用户分析有限。方法：这是一项回顾性的新用户队列研究，使用韩国国民健康保险服务-国家样本队列（2002-2011）。我们确定了bp的新使用者（N=41,854），以及年龄≥50岁的女性中1:1年龄匹配的对照组（N=41,854）。研究人员对参与者进行了长达10年的全因死亡率随访。采用多变量Cox比例风险模型计算风险比（hr），调整年龄和Charlson合并症指数。结果：共纳入83,708名女性。与对照组相比，BP组全因死亡风险较低。BP使用者调整后的风险比为0.47（95%可信区间为0.44-0.49）。结论：在这个全国性的大型韩国队列中，在50岁及以上的女性中，起始BP与全因死亡风险降低相关。这些发现表明bp可能除了预防骨折外还有生存益处。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Bone Metabolism Medicine-Endocrinology, Diabetes and Metabolism

CiteScore

3.70

自引率

0.00%

发文量